SINTX Technologies Inc. (NASDAQ: SINT) stock plunged by 5.47% during the pre-market trading session even though the company has not yet released any updated news or development. SINTX Technologies is a custom ceramics manufacturer that creates and sells sophisticated ceramics for medical and non-medical purposes. SINTX Technologies’ primary competency is the production, analysis, and development of ceramics for external clients. In its FDA-registered, ISO 13485:2016-certified, and ASD9100D-certified manufacturing facility, the Company now produces silicon nitride powders and components.
SINT stock’ Recent Development
SINTX Technologies reported that manufacturing quantities of a new porous, laser-textured monolithic silicon nitride implant composed of FleX SN (sintx.com/materials/flex) for surgical spinal solutions have been delivered. The novel implants were designed and manufactured in partnership with CTL Amedica, and the shipping is the outcome of that collaboration.
In September 2021, SINTX began distributing the new product in order to support an anticipated product launch in Q4. The implants’ porous structure and laser texture is designed to improve SINTX silicon nitride’s osseointegrative capabilities while preserving the material’s antibacterial qualities.
Dr. Sonny Bal, President, and CEO, SINTX Technologies commented,
They are pleased to work with CTL Amedica on the development of these novel implants, which they anticipate will enhance patient outcomes following spine fusion surgery. SINTX is making rapid progress in the development of a new generation of spinal implants owing to their partnership and a newly received Phase 1 funding from the National Institutes of Health.
Furthermore,
SINTX said that it has filed a provisional patent application for enhanced manufacturing processes for silicon nitride materials, including osteogenic implants with higher surface roughness and porosity. CTL Amedica intends to use the technology in its new implants, according to the patent application.
SINTX made significant investments in cutting-edge manufacturing technology, recruiting a world-class staff, and providing best-in-class training to create innovative materials for biomedical, industrial, and antipathogenic applications.
